CD274 and cancer: While connections between the proteins and cancer provide some validation for the usefulness of the misclassified unlabelled proteins as antineoplastic targets, at least one, programmed cell death 1 ligand 1 (UniProt accession Q9NZQ7), is known to be the target of a compound currently undergoing phase II clinical trials as an antineoplastic drug (MPDL3280A).